Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Current Assets: 2019-2025

Historic Current Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $72.0 million.

  • Eton Pharmaceuticals' Current Assets rose 142.02% to $72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year increase of 142.02%. This contributed to the annual value of $41.0 million for FY2024, which is 52.84% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Current Assets stood at $72.0 million, which was up 5.20% from $68.4 million recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Current Assets high stood at $72.0 million for Q3 2025, and its period low was $16.4 million during Q3 2022.
  • Over the past 3 years, Eton Pharmaceuticals' median Current Assets value was $27.2 million (recorded in 2023), while the average stood at $37.3 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Current Assets crashed by 38.06% in 2022 and then surged by 169.10% in 2025.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Current Assets stood at $23.6 million in 2021, then dropped by 15.25% to $20.0 million in 2022, then spiked by 34.17% to $26.8 million in 2023, then soared by 52.84% to $41.0 million in 2024, then skyrocketed by 142.02% to $72.0 million in 2025.
  • Its Current Assets was $72.0 million in Q3 2025, compared to $68.4 million in Q2 2025 and $50.0 million in Q1 2025.